Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics Gets NY State Clinical Lab Permit

NEW YORK (GenomeWeb News) – Good Start Genetics today said that it has received a clinical lab permit from the New York State Department of Health, enabling the firm to offer its GoodStart Select carrier screening tests to in vitro fertilization and other reproductive health physicians in the state.

The Cambridge, Mass.-based firm offers a next-generation sequencing-based carrier screening test. The service provides testing for all 23 diseases recommended by major medical societies and detects common disease-causing mutations and rare pathogenic mutations that older, traditional genotyping-based technologies cannot detect, the firm has said.

Good Start said that with the license from NY State its lab becomes the first to offer extensively validated NGS-based carrier screening in New York.

"Obtaining the New York state license is an important achievement for Good Start, and we're very proud our operation has passed the rigorous New York inspection and approval process," Don Hardison, president and CEO of Good Start Genetics, said in a statement.

The firm noted that since its launch of GoodStart Select in April 2012, its lab has processed more than 100,000 tests.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.